A precision medicine approach to Alzheimer’s disease
By Jan Jarvis
Can an anti-inflammatory drug commonly used for headaches possibly treat or prevent Alzheimer’s disease?
The answer might depend on who’s taking the drug, according to Sid O’Bryant, PhD, Professor in the Center for Alzheimer’s and Neurodegenerative Disease Research at UNT Health Science Center.
There’s substantial evidence that non-steroidal anti-inflammatory drugs (NSAID) have a role in helping brain function, but research at UNTHSC suggests this is only for specific patient subgroups, said O’Bryant. He recently received a $3.5 million grant from the National Institute on Aging to study the use of anti-inflammatory drugs in treating specific subgroups of patients with Alzheimer’s disease.
“We know that inflammation is a huge deal in some, but not all patients,” he said. “With this project, we’ll be able to tell if an NSAID such as naproxen can be used to treat specific patients with Alzheimer’s or even possibly reduce the risk of the disease in some people over time.”
For the study, blood samples from approximately 10,000 patients who have completed clinical trials for treating and preventing Alzheimer’s disease will be examined. It is the first study to test the theory that there are subtypes of patients who benefit from specific drugs, he said. This study looks at those with high inflammation, which is about 20 percent of patients with Alzheimer’s.
“For those 20 percent with high inflammation, the anti-inflammatory drugs should help,” he said. “But for the 20 percent with low inflammation the drugs might not help at all or could make things worse.”
Although prior studies using drugs such as Aleve and Vioxx showed no clear effect on the disease, this study will examine blood samples from those trials to determine if the drugs worked for specific patients. If successful, this precision medicine approach will be expanded to look at different types of drugs that may be of benefit to different subgroups of patients.
Dr. O’Bryant’ s research focuses on specific subgroups of patients rather than trying to find a single miracle drug that cures everyone with Alzheimer’s disease. Previous trials have not been successful, but that was because they tried to treat everyone the same, he said.
“Most trials fail,” Dr. O’Bryant said. “But in reality, they didn’t fail. We just didn’t know who they worked for.
“I believe within five years this work is going to really change the field.”
By Alex Branch A UNT Health Science Center graduate won a national leadership award for creating an educational web resource to help patients who are considering a home birth. Chandler Sparks, DO, MPH, a 2018 graduate of the Texas College of Osteopathic Medicine and a Rural Scholar, ...Read more
Oct 15, 2018
By Sally Crocker Dr. Teresa Wagner’s own experiences as a mother trying to help her daughters through two life-threatening health scares, misdiagnosis and providers’ failure to recognize critical symptoms ignited her passion to lead the charge for improved patient health literacy and better c...Read more
Oct 11, 2018
By Jan Jarvis Whether it’s a feline friend or a gregarious goat, pets play a unique role in people’s lives – including those who work at UNT Health Science Center. Here we feature people from across campus, and the pets that light up their lives. J.D. the bull; Egeenee Daniel...Read more
Oct 10, 2018
By Jan Jarvis Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness. Fortunately, blindness and eye damage can be prevented by suppressing the immune system and treating the disease with corticosteroids, said Sai Chavala, MD, Pr...Read more
Oct 9, 2018